anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cancer is a leading cause of death worldwide, accounting for approximately 10 million deaths or one in six deaths in 2020 (WHO, 2022). According to cancer data published by GLOBOCAN 2020, colorectal cancer is the third most common cancer and the second most common cause of death among all cancer types (GLOBOCAN, 2020). Cancer, the incidence of which is increasing day by day, can cause serious mental problems and psychological effects in the social life of patients, as well as physical difficulties, and this situation negatively affects the course of the disease (Ülger et al, 2014). When the relevant literature is examined for colorectal cancer patients, pain, nausea, vomiting, impaired bowel function, anorexia and delirium are the most common symptoms in colorectal cancer patients (Kocakuşak et al, 2011; El-Shami et al, 2015). Many cancer patients experience psychosocial symptoms in addition to physical symptoms (Ülger et al, 2014). The most common psychosocial symptoms in cancer patients are usually adjustment disorders, depression, anxiety, decreased life satisfaction or loss of self-confidence (Akechi et al, 2001; Ateşci et al, 2003; Seven et al, 2013; Rashid et al, 2021). Since the treatment process of cancer includes a heavy and long process, it is important for patients to receive psycho-social support to protect their mental health and improve their ability to cope with the disease (Ülger et al, 2014). Patient navigation includes the services provided by professionals (navigators) trained in this field to provide education and support to individuals in overcoming the problems they encounter in the health care system, to encourage them to have cancer screenings, and to guide individuals (Dönmez, 2019). When the relevant literature is examined, although there are many studies on the use of navigation programs in cancer patients, no study on symptom management and psychosocial adjustment in individuals diagnosed with colorectal cancer has yet been found (Sussman et al, 2018; Loiselle et al, 2010; Nam et al, 2019; Young et al, 2010; Shum et al, 2014). In this context, the aim of this study is to examine the effect of the nurse navigation program applied to colorectal cancer patients on symptom management and psychosocial adjustment and to contribute to the relevant literature.
The invention relates to development of novel application of existing magnetic Prussian blue nanoparticles to magnetic resonance imaging and targeting photothermal therapy for cancer. Magnetic Prussian blue is a traditional nano material and mainly comprises ferroferric oxide nano cores and Prussian blue nano shells. Prussian blue is an efficient near infrared light heat agent, and a clinical medicine with high biological safety in vivo. Ferroferric oxide has good magnetic resonance imaging and magnetic targeting effects, and has also been applied to the clinic. The existing preparation method of magnetic Prussian blue nanoparticles is mature, simple, green and low in cost. The invention develops novel application of magnetic Prussian blue nanoparticles to magnetic resonance imaging and targeting photothermal therapy for cancer, achieves the integration of utilization of the magnetic Prussian blue nanoparticles to targeting diagnosis and treatment for cancer, and has extremely broad application prospect in diagnosis and treatment of cancer.
The present invention is directed to a method for providing a healthcare management platform. Specifically, an application server may be implemented to provide a website or application for access to various user portals of the platform while providing the facility's management with analytical tools such as real-time patient satisfaction. For example, a patient may be given access to a private patient portal in order to at least submit performance surveys of employees of the facility. A patient may designate guests, who may access the patient portal as would the associated patient. An employee may be given access to a private employee portal in order to at least redeem virtual currency awarded automatically via positive survey results. An administrator may be given access to an administrator portal in order to at least view employee survey data.
As with all therapeutic proteins, there is the potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of incidence of antibodies to CYRAMZA with the incidences of antibodies to other products may be misleading. 

In clinical trials, 86/2890 (3%) of CYRAMZA-treated patients tested positive for treatment-emergent anti-ramucirumab antibodies by an enzyme-linked immunosorbent assay (ELISA). Neutralizing antibodies were detected in 14 of the 86 patients who tested positive for treatment-emergent anti-ramucirumab antibodies.
To provide a novel cosmetic composition that gives a refreshing skin touch during rinsing, can stably keep a bicontinuous microemulsion structure in a wide temperature range, and causes little irritation to the eyes.SOLUTION: A cosmetic composition contains the following components (A)-(G), with a mixed HLB of the components (A) and (B) being 6.5-13.0. Component (A): a polyglycerol fatty acid ester comprising a branched and/or unsaturated fatty acid and a polyglycerol with an average degree of polymerization of glycerols of 7-14. (B): a polyglycerol fatty acid ester comprising a branched and/or unsaturated fatty acid and a polyglycerol with an average degree of polymerization of glycerols of 2-3. (C): a polyglycerol fatty acid ester with an HLB or a mixed HLB of 8.0-17.0. (D): a liquid oil. (E): an anionic surfactant. (F): a polyhydric alcohol component. (G): water.SELECTED DRAWING: None
OBJECTIVES: To describe prevalence of various imaging findings in chronic granulomatous disease (CGD) patients; and find imaging biomarkers for differentiating chest infections caused by different micro-organisms.
METHODS: A retrospective study was conducted on 15 patients (49 scans) with proven CGD. Scans which had a correlative microbiological diagnosis for organisms were included in the analysis. The scans were reviewed by 3 radiologists on a predefined proforma, under the lung parenchymal, airway, pleural, mediastinal, and extrathoracic abnormalities. Analysis of various imaging parameters on a semiquantitative scale was performed, followed by a correlation of each imaging findings with causative organisms.
RESULT: The mean age of presentation was nearly 7 y, with a male preponderance. Definitive proof of causative organisms was obtained in 22 scans. Bacterial infection was found in 7, fungal in 12, tubercular in 2, and viral in 1 scan. Most prevalent thoracic imaging manifestations included lymphadenopathy (commonest), consolidation, nodules, air trapping, and bronchiectasis. Fungal infections showed necrotic conglomerate lymphadenopathy, cavitating nodules, and multilobar consolidation more frequently than bacterial infections (though not statistically significant). Abscesses and lymphadenopathy were the most common extrathoracic manifestations.
CONCLUSION: In patients with CGD, multifocal or multilobar consolidation, mass-like consolidation, cavitating nodules, and conglomerate necrotic lymphadenopathy should alert the radiologist to a possible fungal cause.
A pharmaceutical preparation comprises a stable suspension of a water insoluble alginate for external application to a patient. A colloidal suspension of calcium alginate is conveniently stabilized by use of xantham gum, and/or gellam gum, and/or locust bean gum which act as suspending and gelling agents. The preparation may have a variety of physical forms, ranging from a thin runny gel capable of direct application to the body surface, through a thick gel, to a self-supporting slab, pad or wafer of desired size, shape and thickness which may be held in place with a surgical dressing. The preparation may also be presented in the form of a surgical dressing which carries, e.g. is impregnated with or contains in slab or wafer form, a preparation of the invention. The alginate is haemostatic and also has healing and regranulation properties. The preparation can thus be used in treatment of bleeding wounds and injuries and also non-bleeding wounds such as burns, ulcers and many other conditions.
The safety and effectiveness of CLINOLIPID have been established as a source of calories and essential fatty acids for PN in pediatric patients, including term and preterm neonates, when oral or enteral nutrition is not possible, insufficient, or contraindicated. Use of CLINOLIPID in pediatric patients is supported by evidence from four studies that enrolled pediatric patients, including preterm and term neonates, and additional evidence from clinical studies in adults. Use of CLINOLIPID in older pediatric patients is supported by evidence from two studies in pediatric patients up to 9 years of age treated for a median of 15 and 56 days, respectively, with additional evidence from clinical studies in adults [see Clinical Studies (14.2)]. No clinically significant cases of EFAD were observed in short term pediatric clinical studies. However, one premature neonate in study 3 became at risk for EFAD after 14 days of treatment based on a Holman Index increase above 0.2. This patient’s arachidonic and linoleic acid levels remained within the normal range [see Adverse Reactions (6.1)]. Monitor pediatric patients for laboratory evidence of EFAD, including fatty acid profile (i.e., arachidonic acid) because they may be particularly vulnerable to neurologic complications if adequate amounts of essential fatty acids are not provided [see Warnings and Precautions (5.9)].

In the postmarketing setting, clinical decompensation with rapid infusion of intravenous lipid emulsion in neonates and infants, sometimes fatal, has been reported [see Warnings and Precautions (5.1)]. Because of immature renal function, preterm infants receiving prolonged treatment with CLINOLIPID may be at risk for aluminum toxicity [see Warnings and Precautions (5.8)].
BACKGROUND: Violence against people with intellectual disabilities is unfortunately a reality all over the world, as they are one of the populations most vulnerable to various forms of aggression. Assertive prevention and control measures are crucial to tackle and reduce this problem. The aim of this study was to map and summarize the main measures for preventing and controlling domestic violence against people with intellectual disabilities.  METHODS: This was a scoping review conducted in accordance with the JBI guidelines. The databases consulted were: National Library of Medicine (PubMed); Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science; Excerpta Medica DataBASE (EMBASE); Latin American and Caribbean Health Sciences Literature (LILACS) and SCOPUS. Studies included in this review reported on strategies to address domestic violence against people with intellectual disabilities, published in  the last ten years, in Portuguese, Spanish or English.
RESULTS: A total of 11 studies were included in this review. Six studies had high methodological quality and five had moderate. Cognitive-behavioral intervention programs, educational  technologies and/or auxiliary tools, along with the full participation of people with intellectual disabilities in domestic violence prevention measures are appropriate strategies for dealing with this issue.
CONCLUSION: Domestic violence against people with intellectual disabilities is relatively unexplored in the health-field scientific literature. Prevention and control measures should be developed with the active involvement of people with intellectual disabilities, generating engagement and knowledge. Preventive measures should be adapted to the personal context and conditions of individuals with special needs, such as those with persistent or chronic mental disorders.
The purpose of this study was to investigate the effects of elevated core temperature by exposure to heat stress vs. heat exposure without elevated core temperature (mean skin temperature only) in addition to mental fatigue on aerobic exercise capacity in the heat. Seven highly trained athletes completed two experimental conditions: elevation in core and skin temperatures (hyperthermia: HYP), and skin temperatures (SKIN). Participants performed the AX-Continuous Performance Task and Stroop Task to induce mental fatigue during a warm water immersion at 40 °C (HYP) and a passive seated heat exposure in a climatic chamber at 35 °C and 60% relative humidity (SKIN) for 45 min before exercise. Thereafter, participants performed running trial at 80% maximal oxygen uptake until voluntary exhaustion in the same chamber as the SKIN. Exercise time to exhaustion was significantly shorter in the HYP trial (538 ± 200 s) than in the SKIN trial (757 ± 324 s). Rectal temperature at the end of tasks in the HYP trial increased by 0.86 ± 0.26℃ and was significantly higher (37.69 ± 0.18℃) than that of the SKIN trial (36.96 ± 0.13℃), albeit no significant differences in mean skin temperature. Self-reported mental fatigue using visual analog scale was significantly higher after tasks in both trials, but no significant difference between trials was found. Throughout the trial, salivary cortisol concentration and perceptual responses were not affected by hyperthermia. This study demonstrated that a combination of high core temperature and mean skin temperature, and mental fatigue limit aerobic exercise capacity in highly trained athletes in hot environments compared with heat exposure without an elevation of core temperature.
A sleep care system using fragrances comprises a fragrance spray device, a servomotor, a first lidar, a second lidar, and a sleep evaluation module. The fragrance spray device is mounted with first to n^th fragrance capsules for discharging fragrance substances of different fragrances. The servomotor rotates by a reference angle for each reference time and repeatedly reciprocates in a rotation range from a minimum angle to a maximum angle. The first lidar is mounted on the servomotor, and whenever the servomotor rotates by the reference angle, first distance data is generated by measuring a distance to one body part of a sleeping user located in a front direction. The second lidar is mounted on the servomotor so as to face a different direction from the first lidar, and whenever the servomotor rotates by the reference angle, a distance to another body part of the sleeping user located in the front direction is measured to generate second distance data. The sleep evaluation module determines a large movement and a small movement of the user on the basis of the first distance data and the second distance data, and determines a sleep score on the basis of the number of large and small movements occurring during a sleep time. The fragrance spray device determines combination of emitted fragrances by individually controlling intensity of fragrance substance emission of each of the first to n^th fragrance capsules on the basis of the sleep score.
FIELD: food production industry. SUBSTANCE: mixture is intended for making soft drinks on base of vegetation raw materials. Aforesaid dry mixture includes following components, kg/100 kg of mixture: wild rose fruits, 33-45; hawthorn flours, 17-23; blackberry fruits, 4-6;, sea buckthorn, 8-12; viburnum fruits, 8-12. The soft drink possesses specific organoleptic characteristics and reveals tonic, strengthening and other effects. In addition, substantially enhanced is resistance of organism to ionizing radiation together with immunostimulating action. EFFECT: higher efficiency. 2 ex
For the progressive resistance training we use 11 exercises. The exercises for upper limbs were held in the waiting room before the hemodialysis session. Resistance exercise was carried out in two sets of 15-20 repetitions, the intensity were determined by the method of maximal repetitions, where series were run until exhaustion to momentary exercises (15-20 repetitions) with specific load. The load adjustments or volume were managed when necessary, but necessarily for every 4th week of training. The effort perception should be situated between 12 and 16 on the Borg scale (Borg and Noble, 1974), as proposed by The Life Options Rehabilitation Advisory Council: Exercise for the Patient Dialysis (1995).
The study design is a two-treatment, two-period crossover, double-blind, placebo-controlled design study to investigate the effect of the SGLT2 inhibitor, dapagliflozin, on EC phenotype, EC RNA levels, circulating microRNA (miRNA), and biomarkers in patients with T2DM. Subjects will be randomized to treatment order in a 1:1 ratio to receive SGLT2 inhibitor (dapagliflozin) and then placebo or vice versa in a crossover design. Total study period for each study subject is 14 weeks consisting of: two treatment periods (dapagliflozin and placebo) lasting 6 weeks each (12 weeks total) and a 2 week washout period between treatment periods. Each subject undergoes a washout period of 2 weeks after completing first 6 weeks of treatment with either placebo or dapagliflozin. This is followed by crossover to the alternate treatment period of 6 weeks with dapagliflozin or placebo depending on their first treatment. Randomization will be done in block sizes of 2 or 4. Once assigned to treatment, participants will receive dapagliflozin 10 mg/day or placebo for 6 weeks.
FIELD: medicine.SUBSTANCE: invention refers to therapy and gastroenterology, and can be used to assess the effectiveness of prokinetics at a various degree of bradientery in patients with aggravated chronic obstructive pulmonary disease (COPD) receiving standard therapy, and a prokinetic or a combination of prokinetics. That is ensured by calculating an average bradientery index (index) before the beginning of the therapy and on the 11th day from the beginning of the therapy with scoring a circadian rhythm regularity of the intestinal evacuation function. If the patient has a stool 7 days a week, zero points are assigned; if he/she has a stool 5-6 days - one point is assigned; 3-4 days - two points, 1-2 days - three points. The formula index=(P+P+P+P) /P, wherein Pis the number of patients in the group having zero points, P- having one point, P- having two points, P- having three points; Pis the number of patients in the group. That is followed by calculating a bradientery manifestation coefficient Cbm by formula Cbm=(index 11 day /index 1 day)×100%, wherein index 1 day is the bradientery index before the beginning of the treatment; index 11 day is the bradientery index on the 11day of the treatment. If Cbm makes more than 70%, then the clinical effect of the prokinetic is considered to be unpronounced. If Cbm makes 40% to 70%, the moderate manifestation of the clinical effect of the prokinetic is considered. If Cbm is less than 40%, the clinical effect of the prokinetic is considered to be adequate for the correction of the motor evacuation dysfunction of the gastrointestinal tract.EFFECT: providing the clinical assessment of the clinical effectiveness of the prokinetics of various groups, as well as enabling the selection of the most optimal preparation for the correction of the gastrointestinal motility disorders in the patients with COPD.2 tbl
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to therapy and parasitology, and can be used for treating patients with chronic glomerulonephritis (CGN) combined with chronic opisthorchiasis (CO). That is ensured by introducing a cytoprotector and an antiaggregant, namely Chopytol 0.4 g 4 times a day 30 minutes before meals combined with ticlopidine 0.25 g 2 times a day for 3 weeks. If observing the improvement of the haemostatic system and urine analysis values, the therapy is prolonged for 4 weeks in the previous regimen; while the improvement of the haemostatic system and urine analysis values requires prescribing Chopytol 0.4 g 3 times a day for 3 weeks with underlying administration of ticlopidine 0.25 g 2 times a day. If necessary, the therapeutic course is repeated 6 months after. ^ EFFECT: method allows enabling more evident and permanent therapeutic effect ensured by the correction of endothelial, hemostatic and hepatobiliary dysfunctions in the patients suffering CGN combined with CO with reduced adverse reactions. ^ 2 ex, 2 tbl
Methods and compositions are provided for enhancing the bioadhesive properties of polymers used in drug delivery systems. The bioadhesive properties of a polymer are enhanced by incorporating an anhydride oligomer into the polymer to enhance the ability of the polymer to adhere to a tissue surface such as a mucosal membrane. Anhydride oligomers which enhance the bioadhesive properties of a polymer include oligomers synthesized from dicarboxylic acid monomers, preferably those found in Krebs glycolysis cycle, especially fumaric acid. The oligomers can be incorporated within a wide range of polymers including proteins, polysaccharides and synthetic biocompatible polymers. In one embodiment, anhydride oligomers can be incorporated within polymers used to form or coat drug delivery systems, such as microspheres, which contain a drug or diagnostic agent. The oligomers can either be solubilized and blended with the polymer before manufacture or else used as a coating with polymers over existing systems. The polymers, for example in the form of microspheres, have improved ability to adhere to mucosal membranes, and thus can be used to deliver a drug or diagnostic agent via any of a range of mucosal membrane surfaces including those of the gastrointestinal, respiratory, excretory and reproductive tracts.
Wait-List Control Condition (WLC) group will not receive therapy sessions and will continue usual care with their providers. This group will be offered the same cognitive behavior therapy as the group receiving the CBT-TTF intervention, after the 18 week study period.
An oral care composition comprising a peroxide containing compound dispersed in an orally acceptable carrier, wherein the carrier comprises a humectant and a combination of bioadhesive agents consisting essentially of at least one natural gum and a silicate. Preferred peroxide sources include hydrogen peroxide, carbamide peroxide, calcium peroxide and percarbonates. Preferred humectants include glycerine, sorbitol, propylene glycol, glucose, sucrose and low molecular weight polyethylene glycols. Preferred gums include xanthan gum, carrageenan, alginates, gum karaya, guar gum, gum Arabic and pectins. Preferred silicates include synthetic layered silicates, sodium magnesium silicate, hydrated aluminium silicates and magnesium aluminium silicate. Compositions comprising carabamide peroxide, glycerine, xanthan gum and a layered silica are exemplified. Such compositions show excellent substantivity to the teeth as a result of a synergistic interation between the gelling agents.